Common Antidepressant Shows Potential to Alleviate Long COVID Fatigue
A recent clinical trial suggests that fluvoxamine, a common antidepressant, may help reduce fatigue in patients suffering from long COVID. The study involved 399 participants and showed significant improvements.
A new study has found that fluvoxamine, a low-cost antidepressant, may provide relief for individuals experiencing debilitating fatigue due to long COVID. In a randomized clinical trial involving 399 adults, researchers observed notable improvements in fatigue levels among those taking the medication compared to a placebo group.
Participants reported not only a reduction in fatigue but also enhancements in their overall quality of life. This finding is particularly significant as long COVID continues to affect many individuals, leaving them with persistent symptoms long after the initial infection.
The results of this trial could pave the way for new treatment options for long COVID patients, offering hope for those struggling with chronic fatigue and related issues.